Compare Becton Dickinson and Co (BDX) vs Veritone Inc (VERI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Veritone Inc — how do they compare? Becton Dickinson and Co trades at $180.77 (market cap $49.41B), while Veritone Inc trades at $1.52 (market cap $138.04M). The key difference: Becton Dickinson and Co is far larger — about 357.9× Veritone Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.
| BDX | VERI | |
|---|---|---|
Market Cap | $49.41B | $138.04M |
Sector | Health | Technology |
52-Week High | $185.39 | $8.39 |
52-Week Low | $138.62 | $1.00 |
Enterprise Value | $65.51B | $170.07M |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $180.64, up 0.56% today, near its consensus price target of $183. The stock shows bullish technical signals with strong moving averages and recent earnings beats in Q2 2026. Revenue growth is steady, with Q3 2026 reaching $5 billion, though margins face pressure from tariffs. The company maintains a Dividend Aristocrat status with consistent payouts.
Outlook is cautiously optimistic with analyst consensus leaning buy, but risks include margin compression and debt levels. The stock offers stability through dividends and sector resilience, yet investors should monitor earnings sustainability and competitive threats in the medical technology space.
Veritone (VERI) trades at $1.46, up 1.39% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported a net loss of $111.73M on $92.19M revenue in 2025, with negative profit margins and ROE. Recent news highlights partnerships in AI solutions, but a securities class action lawsuit deadline passed in July 2026.
Outlook remains challenged by persistent losses and high cash burn, offset by analyst optimism with 46% buy ratings. Key risks include the class action, profitability timeline, and competitive AI market. The stock's low price near support levels suggests high volatility potential amid mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Veritone Inc
Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.
Read more on VERI →
